

November 30, 2017  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## **Termination of License Agreement between SymBio Pharmaceuticals Limited and The Medicines Company**

TOKYO, Japan, November 30, 2017 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that the license agreement entered into between SymBio and The Medicines Company (Headquarters: Parsippany, New Jersey, "MDCO") on October 5, 2015 for the exclusive rights to develop and commercialize the patient-controlled pain management drug "IONSYS" or "SyB P-1501" in Japan ("License Agreement"), has terminated effective November 30, 2017, pursuant to the terms of the License Agreement.

As disclosed in MDCO's Form 10-Q filing of November 9, 2017, SymBio initiated an arbitration against MDCO on October 11, 2017, under the rules of the International Chamber of Commerce, seeking damages of at least US\$ 82 million (approximately JPY 9 billion) arising from MDCO's repudiation of the License Agreement. (See SymBio Press Release of November 13, 2017 entitled "Initiation of an Arbitration against The Medicines Company.") In the Request for Arbitration, SymBio claims that MDCO failed to provide SymBio with adequate assurances of performance of MDCO's contractual obligations under the License Agreement in the light of MDCO's decision to (1) discontinue and withdraw IONSYS® from the markets in the US and EU and (2) cease related commercialization activities. SymBio claims such failure by MDCO to be a repudiation and material breach of the License Agreement, resulting in its termination. MDCO's Form 10-Q filing of November 9, 2017 stated that the License Agreement had terminated in October 2017. SymBio disagrees with this statement and has so advised MDCO.

In conjunction with the termination of the License Agreement, SymBio will terminate the development of SyB P-1501 (including the currently-suspended domestic Phase 3 clinical trial), a process that SymBio expects to complete by March 31, 2018.

SymBio will make a prompt announcement should any modification to the financial forecast be necessary.

**[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125

**About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.